Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
Authors
Keywords
AGEs, RAGE, DPP-4, Mannose 6-phosphate/IGF-II receptor
Journal
Cardiovascular Diabetology
Volume 12, Issue 1, Pages 125
Publisher
Springer Nature
Online
2013-08-29
DOI
10.1186/1475-2840-12-125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression
- (2012) Ayako Ojima et al. AMERICAN JOURNAL OF PATHOLOGY
- Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells
- (2012) Hong Li et al. Cardiovascular Diabetology
- Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report
- (2012) Sergio Raposeiras-Roubín et al. Cardiovascular Diabetology
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans
- (2012) Nobuhiro Tahara et al. CLINICAL BIOCHEMISTRY
- Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
- (2012) Sho-ichi Yamagishi et al. CURRENT PHARMACEUTICAL DESIGN
- Atherosclerosis as an Inflammatory Disease
- (2012) Antonino Tuttolomondo et al. CURRENT PHARMACEUTICAL DESIGN
- Positive Association Between Serum Level of Glyceraldehyde-Derived Advanced Glycation End Products and Vascular Inflammation Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomography
- (2012) N. Tahara et al. DIABETES CARE
- Serum Levels of Advanced Glycation End Products (AGEs) are Inversely Associated with the Number and Migratory Activity of Circulating Endothelial Progenitor Cells in Apparently Healthy Subjects
- (2011) So Ueda et al. Cardiovascular Therapeutics
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
- (2011) Zubair Shah et al. CIRCULATION
- Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
- (2011) D. Lamers et al. DIABETES
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes
- (2010) Nga N. Ta et al. ATHEROSCLEROSIS
- Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects
- (2010) Akiko Sarashina et al. CLINICAL THERAPEUTICS
- Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-κB activation
- (2010) Yuichiro Ide et al. MICROVASCULAR RESEARCH
- Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
- (2009) Yuji Ishibashi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- On the origin of serum CD26 and its altered concentration in cancer patients
- (2009) Oscar J. Cordero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication
- (2008) Sho-ichi Yamagishi et al. CURRENT PHARMACEUTICAL DESIGN
- The Role of AGEs in Cardiovascular Disease
- (2008) Karin Jandeleit-Dahm et al. CURRENT PHARMACEUTICAL DESIGN
- A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)
- (2008) Angela Raucci et al. FASEB JOURNAL
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
- Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes
- (2007) Kazuo Nakamura et al. MICROVASCULAR RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started